Back to Search
Start Over
Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease.
- Source :
-
Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2022 Oct; Vol. 18 (10), pp. 1788-1796. Date of Electronic Publication: 2021 Dec 07. - Publication Year :
- 2022
-
Abstract
- Background: Cerebrospinal fluid (CSF) platelet-derived growth factor receptor-β (PDGFRβ) has been proposed as a biomarker of blood-brain barrier (BBB) breakdown. We studied PDGFRβ levels as a biomarker for cerebral amyloid angiopathy (CAA), amnestic mild cognitive impairment (aMCI), or Alzheimer's disease (AD).<br />Methods: CSF PDGFRβ levels were quantified by enzyme-linked immunosorbent assay in patients with CAA, patients with aMCI/AD, and in matched controls. In aMCI/AD we evaluated CSF PDGFRβ both by clinical phenotype and by using the AT(N) biomarker classification system defined by CSF amyloid (A), tau (T), and neurodegeneration (N) biomarkers.<br />Results: PDGFRβ levels were similar in CAA patients and controls (P = .78) and in aMCI/AD clinical phenotype and controls (P = .91). aMCI/AD patients with an AD+ biomarker profile (A+T+[N+]) had increased PDGFRβ levels compared to (A-T-[N-]) controls (P = .006).<br />Conclusion: Our findings indicate that PDGFRβ levels are associated with an AD+ biomarker profile but are not a suitable biomarker for CAA or aMCI/AD clinical syndrome.<br /> (© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Details
- Language :
- English
- ISSN :
- 1552-5279
- Volume :
- 18
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Alzheimer's & dementia : the journal of the Alzheimer's Association
- Publication Type :
- Academic Journal
- Accession number :
- 34874603
- Full Text :
- https://doi.org/10.1002/alz.12506